- Abbott's Volt™ PFA System shows long-term efficacy in treating atrial fibrillation (AFib), with 83.5% of paroxysmal patients arrhythmia-free after 12 months.
- Significant improvement in patients' quality of life, with scores rising from 64.1 to 88.1 over one year.
- The system demonstrates an excellent safety profile, with only 2.7% of patients experiencing primary safety endpoint events.
Abbott (ABT, Financial) has announced compelling 12-month data from its Volt CE Mark Study, highlighting the sustained benefits of using the Volt™ PFA System in patients with atrial fibrillation (AFib). The results were presented at the 2025 Heart Rhythm Society meeting, showcasing the system's effectiveness in treating both paroxysmal (PAF) and persistent AFib patients.
The study results reveal that after 12 months, 83.5% of patients with paroxysmal AFib and 58.1% of patients with persistent AFib remained free from arrhythmia. This marks one of the lowest rates of recurrence in long-term studies concerning PAF patients. Additionally, the quality of life scores for patients improved significantly, increasing from 64.1 to 88.1.
Abbott's Volt PFA System employs high-energy electrical pulses to target cardiac tissue, offering a flexible procedural approach by allowing treatments under light sedation or general anesthesia. The system achieved these results with an average of only 4.7 applications per vein, setting a new standard in procedural efficiency compared to existing market competitors.
Moreover, the safety of the Volt PFA System is underscored by its excellent profile, as only 2.7% of patients experienced primary safety endpoint events, with no occurrences of hemolysis, coronary artery spasm, pulmonary vein stenosis, kidney injury, or phrenic nerve injury. These outcomes indicate a significant advancement in electrophysiology, positioning Abbott's system as a comprehensive solution for treating AFib across varying patient profiles.
Through the Volt CE Mark Study, Abbott aims to expand its reach within the pulsed field ablation market, providing healthcare providers with robust clinical evidence supporting the safe and effective use of the Volt PFA System in treating the spectrum of atrial fibrillation conditions.
